NeuroEPO & Neuroprotective Therapy for Parkinson's Disease

The Role of Neuroprotection in Parkinson's

Parkinson's disease is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra. While standard medications (levodopa and others) replace dopamine and manage symptoms, they do not slow or stop the underlying neurodegeneration.

Neuroprotective therapy aims to address this gap — protecting surviving neurons from further damage, reducing inflammation, and supporting the brain's natural repair mechanisms. This is particularly important in early-to-moderate Parkinson's, where preserving remaining dopaminergic neurons can help maintain function longer.

Cuba has been at the forefront of neuroprotective research, particularly through the development of NeuroEPO — a formulation of recombinant human erythropoietin (EPO) designed to cross the blood-brain barrier and deliver neuroprotective effects directly to brain tissue.

How NeuroEPO Works in Parkinson's

NeuroEPO is based on the discovery that erythropoietin — commonly known as a hormone that stimulates red blood cell production — also has powerful neuroprotective properties in the central nervous system. Cuba's Center for Genetic Engineering and Biotechnology (CIGB) developed a formulation that achieves therapeutic concentrations in the brain.

In Parkinson's disease, NeuroEPO is believed to work through several mechanisms:

• Anti-apoptotic effects — Preventing programmed cell death (apoptosis) of dopaminergic neurons, which is the core pathological process in Parkinson's.

• Anti-inflammatory action — Reducing neuroinflammation in the substantia nigra. Chronic inflammation contributes to ongoing neuronal damage in Parkinson's.

• Antioxidant effects — Scavenging reactive oxygen species that damage neurons. Oxidative stress is a key mechanism in dopaminergic neuron degeneration.

• Neurotrophic support — Promoting the expression of growth factors that support neuronal survival and repair.

• Neuroplasticity promotion — Supporting the brain's ability to form new neural connections, which is essential for functional recovery through rehabilitation.

NeuroEPO is administered as part of CIREN's comprehensive Parkinson's program, not as a standalone treatment. Its effects are believed to be synergistic with intensive rehabilitation — the neuroprotective environment supports the brain's ability to reorganize during therapy.

Clinical Evidence & Research

NeuroEPO has been investigated in preclinical and clinical studies by Cuban research institutions. Studies have explored its neuroprotective effects in models of Parkinson's disease, stroke, and other neurological conditions.

Key research findings include: • Preclinical studies showing protection of dopaminergic neurons in animal models of Parkinson's • Evidence of reduced neuroinflammation and oxidative stress markers • Clinical observations of improved functional outcomes when combined with rehabilitation

It is important to note that NeuroEPO is part of an emerging area of neuroprotective research. While Cuban clinical experience is encouraging, international patients should understand that:

• NeuroEPO is administered under strict medical protocols at CIREN • Treatment is personalized based on each patient's diagnosis and stage • Results vary by individual — no therapeutic outcome is guaranteed • The therapy is part of a comprehensive program, not a standalone treatment • Eligibility is determined by a multidisciplinary medical review

Integration with Rehabilitation

NeuroEPO's neuroprotective effects are believed to be most effective when combined with intensive rehabilitation. The rationale is:

• Neuroprotection preserves neurons — By reducing ongoing neuronal damage, NeuroEPO creates a more favorable environment for rehabilitation to work.

• Neuroplasticity is enhanced — The neurotrophic effects of NeuroEPO may support the brain's ability to form new neural connections during intensive therapy.

• Rehabilitation provides the stimulus — Physical therapy, occupational therapy, and cognitive exercises provide the specific neural stimulation that drives neuroplastic reorganization.

This combined approach — neuroprotective medication plus intensive daily rehabilitation — is the foundation of CIREN's Parkinson's program. Patients receive 4-6 hours of daily therapy across multiple disciplines while the neuroprotective medication supports the brain's capacity to respond to that therapy.

After the 4-week intensive program, patients receive a comprehensive medical report and recommendations for continued care at home, including maintenance medication guidance and home-based exercise protocols.